Key result
Emerging RNA therapies target Lp(a) to reduce residual ASCVD risk in the ~20% affected globally.
Why the study?
Elevated Lp(a) affects approximately 20% of the global population, but specific pharmacological therapies have been unavailable, leaving a major gap in residual risk management.
Design
Review
Lp(a) causality is reinforced; leaves open whether RNA-targeted therapies improve outcomes before practice change.
Lipoprotein(a) [Lp(a)] is a causal, genetically determined risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis (CAVS). Although elevated Lp(a) affects approximately 20% of the global population, specific pharmacological options have long been unavailable, leaving a major gap in residual risk management. This review synthesizes current understanding of Lp(a) molecular architecture, genetics, and metabolism, and integrates mechanistic evidence linking Lp(a) to pro-atherogenic, pro-inflammatory, and pro-thrombotic pathways. We summarize epidemiological and genetic data associating Lp(a) with a broad spectrum of cardiovascular outcomes and discuss current clinical guidelines on screening and risk stratification. Furthermore, we provide an up-to-date overview of the emerging therapeutic landscape, including RNA-targeted therapies and novel oral small molecules. With pivotal phase 3 outcome trials nearing completion, the field is transitioning from viewing Lp(a) as an untreatable biomarker to an actionable therapeutic target, with important implications for precision cardiovascular prevention.
No takes yet. Share an insight, caveat, or question.
Yun et al. (2026) studied this question. Lp(a) is a genetically determined causal risk factor for ASCVD affecting ~20% globally, with emerging RNA-targeted therapies poised to reduce residual cardiovascular risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: